Zydus Lifesciences reports FY26 revenue of Rs. 27,148 crore, Q4 revenue up 16%

Zydus Lifesciences reports FY26 revenue of Rs. 27,148 crore, Q4 revenue up 16%

By: IPP Bureau

Last updated : May 20, 2026 7:31 am



Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance


Zydus Lifesciences Limited has reported strong financial performance for the fourth quarter and full year ended March 31, 2026, driven by revenue growth, improved profitability, and sustained investments in research and development.

For Q4 FY26, revenue from operations stood at Rs. 7,587 crore, reflecting a 16 percent year-on-year increase. EBITDA for the quarter rose 20 percent year-on-year to Rs. 2.554.4 crore, while EBITDA margin improved by 110 basis points to 33.7 percent.

Adjusted net profit for the quarter increased 15 percent year-on-year to Rs. 1,592.9 crore. The company invested Rs. 698.2 crore in research and development during the quarter, accounting for 9.2 percent of revenues, while organic capital expenditure stood at Rs. 357.7 crore.

For the full financial year FY26, revenue from operations increased 17 percent year-on-year to Rs. 27,148.4 crore. EBITDA grew 20 percent to Rs. 8,475.1 crore, with EBITDA margin improving by 80 basis points to 31.2 percent.

Adjusted net profit for FY26 stood at Rs. 5,456.4 crore, registering a 15 percent increase over the previous year. Annual R&D investments were Rs. 2,273.2 crore, representing 8.4 percent of revenues, while organic capital expenditure for the year stood at Rs. 1,714.5 crore.

The company also maintained a strong financial position, with a net debt-to-equity ratio of 0.16x and net debt-to-EBITDA ratio of 0.50x as of March 31, 2026.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, said, “We closed FY26 on a strong note, delivering on our commitments — both on revenue growth and profitability. We are confident our pipeline will drive overall growth visibility while future growth engines begin to deliver. Our near-term priorities are clear: maintain consistent quality standards, integrate our recent acquisitions, and capture synergies swiftly. Finally, our strong balance sheet ensures we have the flexibility to invest and strengthen our businesses further.”

 

Zydus Lifesciences Limited zydus pharmaceutical healthcare Dr. Sharvil Patel

First Published : May 20, 2026 12:00 am